Format

Send to

Choose Destination
J Am Acad Dermatol. 2016 Dec;75(6):1151-1155. doi: 10.1016/j.jaad.2016.06.049. Epub 2016 Sep 28.

Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series.

Author information

1
Department of Dermatology at Roskilde Hospital, Roskilde, Denmark. Electronic address: pmik@regionsjaelland.dk.
2
Department of Dermatology at Deventer Hospital, Deventer, The Netherlands.
3
Department of Dermatology at Erasmus University Medical Center, Rotterdam, The Netherlands.
4
Department of Dermatology at Roskilde Hospital, Roskilde, Denmark.
5
Section of Dermatology and Venereology, Department of Medicine, Huddinge at Karolinska Institutet, Stockholm, Sweden.
6
Department of Dermatology, Stockholm South General Hospital, Stockholm, Sweden.

Abstract

BACKGROUND:

Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the hair follicle. Standard practice of managing acute flares with corticosteroid injection lacks scientific evidence.

OBJECTIVE:

We sought to assess the outcomes of routine treatment using intralesional triamcinolone (triamcinolone acetonide 10 mg/mL) in the management of acute flares in HS.

METHODS:

This was a prospective case series evaluating the effect of intralesional corticosteroids for alleviation of acute flares in HS. Physician- and patient-reported outcomes were noted.

RESULTS:

Significant reductions in physician-assessed erythema (median score from 2-1, P < .0001), edema (median score from 2-1, P < .0001), suppuration (median score from 2-1, P < .0001), and size (median score from 3-1, P < .0001) was demonstrated at follow-up. A significant difference in patient-reported pain visual analog scale scores occurred after 1 day (from 5.5-2.3, P < .005) and from day 1 to day 2 (from 2.3-1.4, P < .002).

LIMITATIONS:

Small study size, open single-arm design, and short follow-up time are the limitations of this study.

CONCLUSION:

Intralesional injection of corticosteroids is perceived as beneficial by physicians and patients in the management of HS flares by reducing pain after 1 day and signs of inflammation approximately 7 days later.

KEYWORDS:

acne inversa; corticosteroids; hidradenitis suppurativa; inflammation; intralesional; skin disease; triamcinolone acetonide

PMID:
27692735
DOI:
10.1016/j.jaad.2016.06.049
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center